Accord’s UK Lenalidomide Launch Kicks Off A Year Of Revlimid Competition
UK Generic Launch Comes Ahead Of Expected Rivals Elsewhere In Europe And US
Executive Summary
Accord has confirmed the launch of a generic lenalidomide rival to Revlimid in the UK. The launch leads off a year that is expected to see the BMS blockbuster also face significant competition elsewhere in Europe and the US.
You may also be interested in...
Accord Adds To Oncology Offering With Orgovyx
Accord Healthcare has struck a European licensing deal with Myovant Sciences for its Orgovyx (relugolix) treatment for advanced hormone-sensitive prostate cancer. The move comes shortly after sister company Accord Biopharma launched the Camcevi (leuprolide) prostate cancer treatment in the US.
Teva Pounces On US Revlimid Opportunity With Four Strength-Offering
Teva has bolstered its oncology offering in the US by moving first on one of the largest small-molecule opportunities in the US: Bristol Myers Squibb’s multi-billion-dollar blockbuster Revlimid (lenalidomide) to treat multiple myeloma.
Dr Reddy’s And BMS Shake Hands On Pomalyst Settlement
Bristol Myers Squibb does not “expect generic entry in the US market prior to the first quarter of 2026” for its Pomalyst treatment for relapsed and refractory multiple myeloma, after reaching a settlement agreement with ANDA sponsor Dr Reddy’s Laboratories.